Guy Katz, MD Profile picture
Mar 21 8 tweets 4 min read
So many amazing teams, having trouble filling out my #RheumMadness bracket!

2021: I thought the tournament came down to clinical trials vs scientific discoveries

Spoiler alert: clinical trials won (😢)

2022: past vs present vs future?

🧵
Cells region: all about future implication
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon
CAR-T and Pim kinases: both cancer therapies that can be repurposed for rheumatic disease

Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!
Animals region: bridging past and future
- Do ancient evolutionary advances (axolotl limbs) have a role in regenerative medicine?
- Do dinosaur skeletons teach us about SpA today?
- Can we improve human tx by studying dog physiology that has been around forever (gout, OA)?
Machines region:
- Predicting TNFi response, JIA subtypes: discovering new ways to use tech in rheum in future, but far from clinical utility
- DECT, PET in LVV: how to optimize tech already at our disposal for dx and monitoring in challenging cases
People region: all about NOW
- Repro health guide, TNFi in cord blood: how can we care for pregnant rheumatic disease patients better now?
- How do we interpret tests we already use all the time (ANA, MRI)?
Ultimately, this comes down to the #BlueRibbonPanel
❓Will they prioritize current clinical utility?
❓Will they take into consideration the historical context of current discoveries?
❓For future implications, is it about magnitude of impact or time to clinical applicability?
Any thoughts on how the Blue Ribbon Panel will decide?

Anyone willing to share their predictions/reasoning?

@DavidLeverenz @Nephro_Sparks @LisaCriscione @AUGarren

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Guy Katz, MD

Guy Katz, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @GuyKatzMD

Mar 25, 2021
Still can't get over how good the #RheumMadness scouting reports are.

Common themes:
✅Most teams are convinced they will win their first round match-up (🤔)
✅Everyone is worried about AAV/SLE teams

Are we being blinded by the bright and shiny AAV/SLE trials?

I say yes.

🧵
First, let's acknowledge that these trials (BLISS-LN, TULIP, PEXIVAS, ADVOCATE) are amazing and definitely worthy competitors. But clinical trials aren't new in #Rheumatology and the other teams offer so much to our field.
IgG4-RD Classification Criteria:

✅Disease many in our field don't understand
✅Describe common + rare manifestations
✅Emphasize IgG4-RD 🆚 mimickers

Think it's too rare to win? We don't even know prevalence (likely under-recognized)!

Hence the criteria...
Read 18 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(